Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canadian company, which develops barium, iodine and carbon active pharmaceutical ingredients. The Company is focused on producing its own barium, iodine and fullerene minerals. The Company, through its subsidiaries, Voyageur Industrial Minerals Ltd. and Voyageur Minerals Inc., is engaged in acquiring, exploring and developing raw materials for pharmaceutical... see more

TSXV:VM - Post Discussion

View:
Post by Finnexas on Oct 31, 2022 9:17am

New News

Total Capital Required over 3 years $36 M (Management has reduced this cost 37% to $22.5M, reduced the timeline, and added iodine, fullerene production and carbon capture = estimated $30M Payback period after start of production 11 Months
Comment by WarrantOfficer on Oct 31, 2022 11:43am
Great news. Now, let's see how / if the new CFO can raise 30M via finincial institutions. 
Comment by lscfa on Nov 03, 2022 3:23pm
The PEA shows capex is $5 mil, $15 mil and $16 mil in years 1, 2, 3 so don't have to raise the whole thing now.
Comment by WarrantOfficer on Nov 04, 2022 9:07am
My thoughts are go for the entire 30M +. Interest rates are likely to go up over the next while. Lock in now. The PEA and IRR are very favourable. Value of Frances Creek continues to rise, world contrast and supply shortages, aging population, trade and combat wars all raise the likely hood of Voyageur strategic plan execution. Companies have been able to borrow money from lending institutions ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1